Alvin Chandra1, Eldrin F Lewis1, Brian L Claggett1, Akshay S Desai1, Milton Packer2, Michael R Zile3, Karl Swedberg4,5, Jean L Rouleau5,6, Victor C Shi7, Martin P Lefkowitz7, Tzvetana Katova8, John J V McMurray9, Scott D Solomon1. 1. Brigham and Women's Hospital, Boston, Massachusetts. 2. Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas. 3. Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston. 4. Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. 5. National Heart and Lung Institute, Imperial College, London, England. 6. Institut Cardiologie de Montreal, Université de Montreal, Montreal, Quebec, Canada. 7. Novartis, East Hanover, New Jersey. 8. National Hospital of Cardiology, Sofia, Bulgaria. 9. British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland.
Abstract
Importance: Health-related quality of life (HRQL) of patients with heart failure is markedly reduced compared with that in patients with other chronic diseases, demonstrating substantial limitations in physical and social activities. In the Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, sacubitril/valsartan improved overall HRQL compared with enalapril, as determined by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Objective: To examine the effects of sacubitril/valsartan on physical and social activities. Design, Setting, and Participants: The PARADIGM-HF trial was a randomized, double-blind, active treatment-controlled clinical trial performed from December 8, 2009, to March 31, 2014, in 8399 patients with New York Heart Association class II to IV disease and a left ventricular ejection fraction of 40% or less at 1043 centers in 38 countries. Data analysis was performed from August 1, 2017, to December 25, 2017. Interventions: Sacubitril/valsartan, 200 mg twice daily, or enalapril, 10 mg twice daily. Main Outcomes and Measures: Patients completed HRQL assessments using the KCCQ at randomization, 4-month, 8-month, and annual visits. The effect of sacubitril/valsartan on components of the physical and social limitation sections of the KCCQ at 8 months and longitudinally and related biomarkers and clinical outcomes were studied. Results: At baseline, 7618 of 8399 patients (90.7%) (mean [SD] age, 64 [11] years; 5987 [78.6%] male and 1631 [21.4%] female) completed the initial KCCQ assessment. Patients reported the greatest limitations at baseline in jogging and sexual relationships. Patients receiving sacubitril/valsartan had significantly better adjusted change scores in most physical and social activities at 8 months and during 36 months compared with those receiving enalapril. The largest improvement over enalapril was in household chores (adjusted change score difference, 2.35; 95% CI, 1.19-3.50; P < .001) and sexual relationships (adjusted change score difference, 2.72; 95% CI, 0.97-4.46; P = .002); both persisted through 36 months (overall change score difference, 1.69 [95% CI, 0.78-2.60], P < .001; and 2.36 [95% CI, 1.01-3.71], P = .001, respectively). Conclusions and Relevance: In patients with heart failure with reduced ejection fraction, sacubitril/valsartan significantly improved nearly all KCCQ physical and social activities compared with enalapril, with the largest responses in household chores and sexual relationships. In addition to reduced likelihood of cardiovascular death, all-cause mortality, and heart failure hospitalization, sacubitril/valsartan may improve limitations in common activities in these patients. Trial Registration: clinicaltrials.gov Identifier: NCT01035255.
RCT Entities:
Importance: Health-related quality of life (HRQL) of patients with heart failure is markedly reduced compared with that in patients with other chronic diseases, demonstrating substantial limitations in physical and social activities. In the Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, sacubitril/valsartan improved overall HRQL compared with enalapril, as determined by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Objective: To examine the effects of sacubitril/valsartan on physical and social activities. Design, Setting, and Participants: The PARADIGM-HF trial was a randomized, double-blind, active treatment-controlled clinical trial performed from December 8, 2009, to March 31, 2014, in 8399 patients with New York Heart Association class II to IV disease and a left ventricular ejection fraction of 40% or less at 1043 centers in 38 countries. Data analysis was performed from August 1, 2017, to December 25, 2017. Interventions: Sacubitril/valsartan, 200 mg twice daily, or enalapril, 10 mg twice daily. Main Outcomes and Measures: Patients completed HRQL assessments using the KCCQ at randomization, 4-month, 8-month, and annual visits. The effect of sacubitril/valsartan on components of the physical and social limitation sections of the KCCQ at 8 months and longitudinally and related biomarkers and clinical outcomes were studied. Results: At baseline, 7618 of 8399 patients (90.7%) (mean [SD] age, 64 [11] years; 5987 [78.6%] male and 1631 [21.4%] female) completed the initial KCCQ assessment. Patients reported the greatest limitations at baseline in jogging and sexual relationships. Patients receiving sacubitril/valsartan had significantly better adjusted change scores in most physical and social activities at 8 months and during 36 months compared with those receiving enalapril. The largest improvement over enalapril was in household chores (adjusted change score difference, 2.35; 95% CI, 1.19-3.50; P < .001) and sexual relationships (adjusted change score difference, 2.72; 95% CI, 0.97-4.46; P = .002); both persisted through 36 months (overall change score difference, 1.69 [95% CI, 0.78-2.60], P < .001; and 2.36 [95% CI, 1.01-3.71], P = .001, respectively). Conclusions and Relevance: In patients with heart failure with reduced ejection fraction, sacubitril/valsartan significantly improved nearly all KCCQ physical and social activities compared with enalapril, with the largest responses in household chores and sexual relationships. In addition to reduced likelihood of cardiovascular death, all-cause mortality, and heart failure hospitalization, sacubitril/valsartan may improve limitations in common activities in these patients. Trial Registration: clinicaltrials.gov Identifier: NCT01035255.
Authors: Glenn N Levine; Elaine E Steinke; Faisal G Bakaeen; Biykem Bozkurt; Melvin D Cheitlin; Jamie Beth Conti; Elyse Foster; Tiny Jaarsma; Robert A Kloner; Richard A Lange; Stacy Tessler Lindau; Barry J Maron; Debra K Moser; E Magnus Ohman; Allen D Seftel; William J Stewart Journal: Circulation Date: 2012-01-19 Impact factor: 29.690
Authors: Eldrin F Lewis; Brian L Claggett; John J V McMurray; Milton Packer; Martin P Lefkowitz; Jean L Rouleau; Jiankang Liu; Victor C Shi; Michael R Zile; Akshay S Desai; Scott D Solomon; Karl Swedberg Journal: Circ Heart Fail Date: 2017-08 Impact factor: 8.790
Authors: Mary Medina; Cynthia Walker; Elaine E Steinke; David W Wright; Victoria Mosack; Mohammad Hussam Farhoud Journal: Prog Cardiovasc Nurs Date: 2009-12
Authors: David C Pryde; Andrew S Cook; Denise J Burring; Lyn H Jones; Stephanie Foll; Michelle Y Platts; Vivienne Sanderson; Martin Corless; Alan Stobie; Donald S Middleton; Laura Foster; Laura Barker; Piet Van Der Graaf; Peter Stacey; Christopher Kohl; Sara Coggon; Kevin Beaumont Journal: Bioorg Med Chem Date: 2006-10-06 Impact factor: 3.641
Authors: Milton Packer; John J V McMurray; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael Zile; Karl Andersen; Juan Luis Arango; J Malcolm Arnold; Jan Bělohlávek; Michael Böhm; Sergey Boytsov; Lesley J Burgess; Walter Cabrera; Carlos Calvo; Chen-Huan Chen; Andrej Dukat; Yan Carlos Duarte; Andrejs Erglis; Michael Fu; Efrain Gomez; Angel Gonzàlez-Medina; Albert A Hagège; Jun Huang; Tzvetana Katova; Songsak Kiatchoosakun; Kee-Sik Kim; Ömer Kozan; Edmundo Bayram Llamas; Felipe Martinez; Bela Merkely; Iván Mendoza; Arend Mosterd; Marta Negrusz-Kawecka; Keijo Peuhkurinen; Felix J A Ramires; Jens Refsgaard; Arvo Rosenthal; Michele Senni; Antonio S Sibulo; José Silva-Cardoso; Iain B Squire; Randall C Starling; John R Teerlink; Johan Vanhaecke; Dragos Vinereanu; Raymond Ching-Chiew Wong Journal: Circulation Date: 2014-11-17 Impact factor: 29.690
Authors: John J V McMurray; Milton Packer; Akshay S Desai; Jim Gong; Martin P Lefkowitz; Adel R Rizkala; Jean Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile Journal: Eur J Heart Fail Date: 2013-04-05 Impact factor: 15.534
Authors: Pratyaksh K Srivastava; Brian L Claggett; Scott D Solomon; John J V McMurray; Milton Packer; Michael R Zile; Akshay S Desai; Jean L Rouleau; Karl Swedberg; Gregg C Fonarow Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676
Authors: Yevgeniy Khariton; Gregg C Fonarow; Suzanne V Arnold; Ann Hellkamp; Michael E Nassif; Puza P Sharma; Javed Butler; Laine Thomas; Carol I Duffy; Adam D DeVore; Nancy M Albert; J Herbert Patterson; Fredonia B Williams; Kevin McCague; John A Spertus Journal: JACC Heart Fail Date: 2019-09-11 Impact factor: 12.035
Authors: José Manuel Rubio Campal; Hugo Del Castillo; Belén Arroyo Rivera; Carmen de Juan Bitriá; Mikel Taibo Urquia; Pepa Sánchez Borque; Ángel Miracle Blanco; Loreto Bravo Calero; David Martí Sánchez; José Tuñón Fernández Journal: Cardiol J Date: 2021-02-26 Impact factor: 2.737